Recent Finacing
Recent Raise
Accession Therapeutics is an Oxford-based biotech developing tumor-targeted immunotherapies using its tunable TROCEPT platform to deliver anti-cancer transgene payloads, advancing TROCEPT-01 and a second programme toward clinical trials.